Monogenic Kidney Disorders as Hidden Drivers of Electrolyte Imbalance and Hypertension

Abstract

Hypertension is the leading modifiable risk factor for cardiovascular disease, stroke, and chronic kidney disease worldwide. Although most cases are essential hypertension, a subset of patients harbors monogenic disorders that disrupt how the kidneys control electrolyte balance and blood pressure regulation. These rare conditions provide important insights into the fundamental physiological mechanisms that link tubular sodium transport, extracellular volume homeostasis, and systemic hemodynamics. The distal nephron is crucial in fine-tuning sodium and potassium balance through tightly regulated transport systems, such as the sodium–chloride cotransporter (NCC) in the distal convoluted tubule and the epithelial sodium channel (ENaC) in the collecting duct. Genetic perturbations of these pathways can markedly disrupt electrolyte balance and blood pressure. Monogenic hypertensive disorders exemplify these mechanisms. Liddle syndrome results from gain-of-function mutations in ENaC subunits, resulting in sodium retention, hypokalemia, and suppressed renin–aldosterone levels. Conversely, Gordon syndrome (pseudohypoaldosteronism type II) is caused by the dysregulation of the with-no-lysine (K) kinase–SPS1-related proline/alanine-rich kinase signaling pathway, resulting in NCC overactivation and the paradoxical concurrence of hypertension and hyperkalemia. Apparent mineralocorticoid excess results from deficiency of 11β-hydroxysteroid dehydrogenase type 2, resulting in the inappropriate activation of the mineralocorticoid receptor by cortisol and subsequent sodium retention. Together, these disorders illustrate how discrete defects in distal nephron transport pathways induce characteristic electrolyte signatures while converging on the shared phenotype of hypertension. Understanding these genetic mechanisms may provide insight into fundamental renal physiology and facilitate the use of precision diagnostic and therapeutic approaches for patients with atypical or treatment-resistant hypertension.

INTRODUCTION

Hypertension is the leading preventable risk factor for cardiovascular disease, stroke, and chronic kidney disease worldwide [1]. Although most cases are classified as essential hypertension, a complex, polygenic condition influenced by environmental factors, lifestyle, and aging, a subset of patients harbor secondary and potentially reversible causes. Among these, monogenic kidney disorders represent rare but clinically important causes of hypertension, accounting for a small proportion of cases in the general population but a substantially higher proportion among individuals with early-onset or treatment-resistant hypertension. These disorders offer valuable insights into the fundamental physiological mechanisms governing blood pressure regulation and fluid–electrolyte homeostasis [2].

Arthur Guyton advanced the kidney-centered model of blood pressure control by establishing that the kidney primarily determines long-term arterial pressure through the pressure–natriuresis relationship [3]. This framework presents that sustained hypertension occurs when renal sodium excretion is impaired, necessitating a higher arterial pressure to achieve sodium balance. Genetic mutations that disrupt kidney sodium regulation or potassium homeostasis effectively shift this pressure–natriuresis curve, resetting the systemic blood pressure set point at a higher level [4,5]. Monogenic kidney disorders exemplify this principle, as mutations that affect tubular transport proteins, ion channels, and regulatory signaling pathways disrupt renal sodium reabsorption, extracellular volume homeostasis, and potassium balance [6,7]. Clinically, these molecular defects manifest as early-onset or treatment-resistant hypertension. These abnormalities are often accompanied by characteristic electrolyte abnormalities and acid–base disturbances. Importantly, these conditions often masquerade as primary hypertension, leading to delayed diagnosis and suboptimal targeted therapy.

This review aimed to explore the molecular mechanisms underlying monogenic hypertensive disorders, which would emphasize the transition from tubular transport defects to systemic clinical phenotypes. Understanding these genetic drivers can help clinicians transition from empirical treatment to precision medicine by targeting specific molecular pathways disrupted.

PATHOPHYSIOLOGY OF TUBULAR SODIUM TRANSPORT AND HEMODYNAMICS

The human kidney filters approximately 180 L of glomerular ultrafiltrate daily; however, only < 1% of the filtered sodium load is ultimately excreted in the urine [8,9]. This remarkable efficiency is attributed to the coordinated activity of specialized transporters distributed along the nephrons. Among these segments, distal nephrons, particularly the distal convoluted tubule (DCT) and collecting duct (CD), play a disproportionate role in blood pressure regulation, as the final hormonally regulated adjustments in sodium and potassium balance occur in the nephrons [10,11].

At the molecular level, the sodium–chloride cotransporter (NCC) primarily mediated sodium reabsorption in the DCT, whereas the principal cells of the CD reabsorb sodium through the epithelial sodium channel (ENaC) [5]. Activities of these transport systems are regulated rather than static under the control of an intricate signaling network that includes serine–threonine kinases (such as the with-no-lysine [K] kinase [WNK] family and their downstream SPS1-related proline/alanine-rich kinase [SPAK]/oxidative stress–responsive kinase 1 [OSR1]) and ubiquitin ligases (notably NEDD4-2) [12,13,14]. Genetic mutations that enhance the activity or expression of these transporters can lead to increased sodium retention and secondary water reabsorption, leading to extracellular fluid volume expansion. This volume expansion is associated with increased cardiac output and may contribute to high systemic vascular resistance, thereby sustaining hypertension.

Simultaneously, enhanced sodium reabsorption, particularly via ENaC, enhances the lumen-negative transepithelial potential difference in the distal nephron. These electrical gradients drive potassium and hydrogen ion secretion, predisposing to hypokalemia and metabolic alkalosis [11,15]. These electrolyte and acid–base abnormalities often provide the earliest clinical clues underlying monogenic disorder of tubular sodium handling [6].

MONOGENIC HYPERTENSIVE DISORDERS

Liddle syndrome

This syndrome is the prototypical form of monogenic salt-sensitive hypertension. This autosomal dominant disorder is characterized by severe, early-onset hypertension [16]. The molecular defect most commonly involves gain-of-function mutations in SCNN1B or SCNN1G, which encode ENaC β- and γ-subunits, respectively [17]. SCNN1A (α-subunits) mutations are rare but have also been described [18].

Under physiological conditions, ENaC surface expression is tightly regulated by the E3 ubiquitin ligase NEDD4-2, which recognizes a proline-risk “PY motif” located in the cytoplasmic C-terminus of the β- and γ-subunits and targets the channel for ubiquitination and proteasomal degradation (Fig. 1) [5,19]. In Liddle syndrome, truncating or missense mutations disrupt this PY motif, which inhibits NEDD4-2 binding [17]. Consequently, ENaC accumulates at the apical membrane of principal cells in the CD and remains constitutively active.

Fig. 1. Physiological regulation of sodium transport in principal cells of the distal nephron and its dysregulation in Liddle syndrome. Under normal conditions, aldosterone binds to the MR, leading to increased transcription of ENaC subunits and SGK1. SGK1 enhances ENaC activity in part by inhibiting the E3 ubiquitin ligase NEDD4-2, which normally binds to the PY motif of ENaC subunits and promotes channel ubiquitination and internalization. This tightly regulated balance maintains appropriate sodium reabsorption. In Liddle syndrome, gain-of-function mutations in ENaC disrupt the PY motif, preventing NEDD4-2–mediated degradation and resulting in constitutive ENaC activation and sodium reabsorption independent of aldosterone.

BK, large-conductance calcium-activated potassium channel; CD, collecting duct; ENaC, epithelial sodium channel; HRE, hormone response element; MR, mineralocorticoid receptor; NEDD4-2, neural precursor cell expressed developmentally down-regulated 4-2; ROMK, renal outer medullary potassium channel; SGK1, serum and glucocorticoid-regulated kinase 1.

The clinical phenotype reflects mineralocorticoid excess, often referred to as pseudoaldosteronism. Enhanced ENaC activity leads to increased sodium reabsorption and extracellular volume expansion, which in turn suppresses the renin–angiotensin–aldosterone system to very low or undetectable levels [5,9]. However, given the autonomous and aldosterone-independent nature of sodium reabsorption, hypertension persists despite low plasma renin and aldosterone concentrations [20]. This distinction is clinically important for diagnosis. In contrast to primary aldosteronism, Liddle syndrome is characterized by suppressed aldosterone, rendering mineralocorticoid receptor (MR) antagonists, such as spironolactone, ineffective [16,20]. Alternatively, direct ENaC inhibitors, particularly amiloride or triamterene, produce a marked therapeutic response [16,20].

At the cellular level, high sodium influx through ENaC enhances basolateral Na⁺/K⁺-ATPase activity, promoting potassium uptake into cells (Fig. 1). Concurrently, augmented apical sodium entry generates a more lumen-negative transepithelial potential difference in distal nephrons. This electrical gradient drives potassium secretion through apical potassium channels, such as renal outer medullary potassium channel (ROMK), and facilitates hydrogen ion secretion by α-intercalated cells [21]. The net effect is renal potassium wasting and increased acid excretion, resulting in hypokalemia and metabolic alkalosis [21,22].

Liddle syndrome reflects how dysregulation of a distal nephron transporter can mimic the hemodynamic and electrolyte phenotype of mineralocorticoid excess without hormonal activation.

Gordon syndrome (pseudohypoaldosteronism type II)

This syndrome, also known as pseudohypoaldosteronism type II or familial hyperkalemic hypertension, is a paradoxical form of monogenic hypertension characterized by the triad of hypertension, hyperkalemia, and hyperchloremic metabolic acidosis [23]. In contrast to Liddle syndrome, which is driven by excessive ENaC activity in the CD, Gordon syndrome arises primarily from dysregulated sodium transport in the DCT [24].

The disorder is caused by mutations in genes encoding components of the WNK signaling pathway (e.g., WNK1, WNK4, Kelch-like protein 3 [KLHL3], and Cullin 3 [CUL3]). WNK1 and WNK4 are serine–threonine protein kinases that form a phosphorylation cascade with SPAK and OSR1, ultimately regulating the activity of cation–chloride cotransporters, particularly the NCC (Fig. 2A) [25,26]. WNK–SPAK/OSR1 pathway activation enhances NCC phosphorylation and increases its activity at the apical membrane of DCT cells [23].

Fig. 2. Mechanisms of Gordon syndrome. (A) In the DCT, activation of the WNK–SPAK/OSR1 signaling cascade increases the activity of the NCC, enhancing sodium and chloride reabsorption. Gain-of-function mutations in WNK1 or WNK4 increase WNK kinase activity, whereas loss-of-function mutations in CUL3 or KLHL3 impair ubiquitin-mediated degradation of WNK kinases, leading to their accumulation and sustained NCC activation. (B) Increased sodium reabsorption in the DCT reduces distal sodium delivery to the CD, thereby decreasing ENaC-mediated sodium uptake and impairing potassium secretion through apical potassium channels such as ROMK, resulting in hyperkalemia.

CD, collecting duct; CUL3, Cullin 3; DCT, distal convoluted tubule; ENaC, epithelial sodium channel; KLHL3, Kelch-like protein 3; NCC, sodium–chloride cotransporter; OSR1, oxidative stress–responsive kinase 1; ROMK, renal outer medullary potassium channel; SPAK, SPS1-related proline/alanine-rich kinase; WNK, with-no-lysine (K) kinase.

Recent studies have further demonstrated that WNK kinases are directly regulated by intracellular chloride [27,28]. Low intracellular chloride concentration, as seen in hypokalemia or reduced effective circulating volume, relieves inhibitory binding at a conserved chloride-binding site within WNK kinases, leading to activation of WNK kinases (particularly WNK4) and the downstream WNK–SPAK/OSR1 signaling cascade [29]. This mechanism establishes WNK4 as a key intracellular chloride sensor in the DCT and provides a mechanistic basis for the inverse relationship between dietary potassium intake and NCC activity [29]. In addition, kidney-specific WNK1 functions as a signal amplifier by promoting the formation of WNK bodies, thereby enhancing WNK–SPAK/OSR1-mediated NCC activation in response to changes in potassium balance [30]. This mechanism enables the distal nephron to translate small fluctuations in plasma potassium into robust alterations in sodium transport [30].

Under normal conditions, WNK abundance is tightly controlled by a Cullin-RING E3 ubiquitin ligase complex composed of CUL3 and KLHL3, which targets WNK kinases for ubiquitination and proteasomal degradation (Fig. 2A) [24]. CUL3 or KLHL3 mutations impair this degradation process, leading to the accumulation of WNK kinases and constitutive activation of NCC [26]. Similarly, gain-of-function WNK1 or WNK4 mutations directly enhance NCC activity [23,24]. The net effect is excessive sodium and chloride reabsorption in the DCT.

Previous genotype–phenotype studies have demonstrated substantial clinical variability [25,26]. CUL3 mutations and recessive KLHL3 variants are typically associated with earlier onset and more severe phenotypes, whereas dominant KLHL3, WNK4, and WNK1 intron 1 deletion tend to produce intermediate forms [25]. Mild phenotypes have shown association with specific WNK1 acidic motif variants.

The resulting hyperkalemia provides important mechanistic insight. Enhanced NCC-mediated sodium reabsorption in the DCT eases sodium delivery to the downstream CD, where ENaC-dependent sodium uptake normally generates a lumen-negative potential that triggers potassium secretion [23]. Reduced distal sodium delivery diminishes this electrical gradient, impairing potassium secretion through ROMK channels [22,24]. Additionally, WNK signaling directly suppresses ROMK expression and activity, further limiting renal potassium excretion (Fig. 2B) [24]. The combined effect of systemic hyperkalemia and reduced hydrogen ion secretion leads to hyperchloremic metabolic acidosis. Gordon illustrates how increased sodium reabsorption at an upstream nephron segment can paradoxically produce hyperkalemia, underscoring the tight coupling between segmental sodium handling and potassium homeostasis [24].

Liddle and Gordon syndromes represent physiologic opposites, demonstrating how different distal nephron sodium transport defects can produce mirror-image potassium phenotypes.

Apparent mineralocorticoid excess (AME)

AME is a rare autosomal recessive disorder characterized by severe, early-onset hypertension, hypokalemia, metabolic alkalosis, and renin and aldosterone suppression [31]. It results from loss-of-function mutations in HSD11B2, which encodes the 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) enzyme. 11β-HSD2 functions as a critical “gatekeeper” for the MR in aldosterone-sensitive tissues, such as distal nephrons [32,33]. Although the MR has a similar affinity for cortisol and aldosterone, circulating cortisol concentrations are several hundredfold higher than those of aldosterone. Under physiological conditions, 11β-HSD2 protects the MR by rapidly converting cortisol into cortisone, its inactive metabolite, thereby ensuring that aldosterone remains the primary physiological ligand activating the MR [32,34].

In AME, 11β-HSD2 deficiency prevents this protective cortisol inactivation (Fig. 3). Consequently, cortisol freely binds to and activates the MR in distal nephrons, mimicking AME despite low circulating aldosterone levels [31]. MR activation upregulates ENaC activity and basolateral Na⁺/K+-ATPase function, promoting sodium retention and extracellular volume expansion [31]. The resulting volume expansion suppresses the renin–angiotensin–aldosterone system, producing the characteristic biochemical profile of low renin and low aldosterone.

Fig. 3. Mechanisms of apparent mineralocorticoid excess syndrome. In normal physiology, 11β-HSD2 converts cortisol to inactive cortisone, thereby protecting the MR from activation by cortisol. In apparent mineralocorticoid excess syndrome, deficiency of 11β-HSD2 permits cortisol to bind to and activate the MR in the distal nephron, mimicking a state of mineralocorticoid excess despite low circulating aldosterone levels. This results in increased ENaC activity, sodium retention, extracellular volume expansion, and suppression of the renin–angiotensin–aldosterone system.

11β-HSD2, 11β-hydroxysteroid dehydrogenase type 2; BK, large-conductance calcium-activated potassium channel; CD, collecting duct; ENaC, epithelial sodium channel; HRE, hormone response element; MR, mineralocorticoid receptor; NEDD4-2, neural precursor cell expressed developmentally down-regulated 4-2; ROMK, renal outer medullary potassium channel; SGK1, serum and glucocorticoid-regulated kinase 1.

Enhanced sodium reabsorption through ENaC also generates a lumen-negative potential difference in the CD, driving potassium and hydrogen ion secretion. Consequently, hypokalemia and metabolic alkalosis occur, closely resembling the electrolyte phenotype observed in Liddle syndrome. However, the underlying mechanism involves inappropriate MR activation rather than intrinsic channel dysregulation.

Clinically, AME typically presents in early childhood with severe hypertension, polyuria, and polydipsia caused by impaired urinary concentrating ability [35]. Affected children often may develop failure to thrive, and nephrocalcinosis. The disease can lead to serious complications, including early-onset stroke [36].

Geller syndrome

Geller syndrome is an extremely rare form of autosomal dominant hypertension caused by activating mutations in the MR gene NR3C2 [6,37]. These mutations alter the ligand specificity of the MR, allowing steroids that normally function as antagonists, particularly progesterone, to act as potent agonists. Consequently, MR activation stimulates sodium reabsorption in distal nephrons, leading to hypertension, hypokalemia, and renin and aldosterone suppression [37].

Clinically, Geller syndrome often presents as pregnancy-associated hypertension because circulating progesterone levels increase markedly during gestation [38]. In affected individuals, progesterone activates the mutant MR, triggering excessive sodium retention and severe hypertension. Importantly, MR antagonists, such as spironolactone, may paradoxically worsen hypertension in these patients because spironolactone can act as an agonist at the mutant receptor [37]. Therefore, recognition of this disorder helps avoid inappropriate therapy [6].

DIAGNOSTIC APPROACH AND THE SHIFT TOWARD PRECISION MEDICINE

The diagnostic evaluation of genetic kidney disease often begins on the onset of resistant hypertension, defined as blood pressure that remains uncontrolled despite the use of multiple antihypertensive agents. The presence of early-onset hypertension and/or cerebrovascular accident at a young age should prompt further metabolic and endocrine evaluation [39].

The initial screening should include the measurement of plasma renin activity and plasma aldosterone levels, along with a comprehensive metabolic panel to assess potassium and bicarbonate levels [5,6,23]. A biochemical profile characterized by “low-renin, low-aldosterone” is a hallmark of Liddle syndrome or AME, whereas “low-renin, high-aldosterone” suggests primary aldosteronism (Table 1). If hyperkalemia and metabolic acidosis occur with hypertension, Gordon syndrome becomes the primary suspect [23].

Table 1. Monogenic hypertensive disorders affecting distal nephron sodium transport.

Disorder	Gene	Inheritance	Age at onset	Key mechanism	Nephron target (transporter)	Electrolyte phenotype	Renin	Aldosterone	Targeted therapy
Liddle syndrome	SCNN1B, SCNN1G (rarely SCNN1A)	AD	Childhood to young adulthood	Gain-of-function ENaC due to impaired NEDD4-2–mediated degradation	Collecting duct (ENaC)	Hypokalemia, metabolic alkalosis	Low	Low	ENaC inhibitors (amiloride, triamterene)
Gordon syndrome	WNK1, WNK4, CUL3, KLHL3	AD	Early childhood to adulthood	Dysregulation of the WNK–SPAK/OSR1 signaling pathway leading NCC overactivation	Distal convoluted tubule (NCC)	Hyperkalemia, hyperchloremic metabolic acidosis	Low	Low to normal	Thiazide diuretics
		AD or AR
Apparent mineralocorticoid excess	HSD11B2	AR	Infancy/early childhood	Loss of 11β-HSD2 activity allowing cortisol activation of MR	Collecting duct (MR-ENaC)	Hypokalemia, metabolic alkalosis	Low	Low	MR antagonists, ENaC blockers
Geller syndrome	NR3C2	AD	Adolescence to adulthood (often pregnancy-associated)	Activating mutation of the MR allowing progesterone or spironolactone to act as agonists	Collecting duct (MR-ENaC)	Hypokalemia (variable)	Low	Low	Amiloride; avoid spironolactone

11β-HSD2, 11β-hydroxysteroid dehydrogenase type 2; AD, autosomal dominant; AR, autosomal recessive; ENaC, epithelial sodium channel; MR, mineralocorticoid receptor; NCC, sodium–chloride cotransporter; OSR1, oxidative stress–responsive kinase 1; SPAK, SPS1-related proline/alanine-rich kinase; WNK, with-no-lysine (K) kinase.

Definitive diagnosis is increasingly achieved through genetic testing, including targeted gene panels, whole-exome sequencing, and whole-genome sequencing. Identifying the specific genetic mutation is not just an academic exercise; it has direct therapeutic implications. Precision medicine allows clinicians to bypass ineffective standard treatments, such as using angiotensin-converting enzyme inhibitors in a patient with Liddle syndrome and spironolactone in Geller syndrome, and move directly to the molecularly appropriate blocker (Table 1) [6,37].

This targeted approach prevents the devastating long-term consequences of uncontrolled hypertension, such as failure to thrive, premature stroke, chronic kidney disease, and heart failure, and improves long-term prognosis [17,23,36,40]. Genetic diagnosis also enables screening of family members, facilitates the identification of asymptomatic carriers, and informs genetic counseling and family planning.

CONCLUSION AND FUTURE PERSPECTIVES

Genetic kidney diseases represent important yet frequently under-recognized drivers of hypertension and cardiovascular morbidity [5,37,41]. Once considered rare textbook curiosities, there disorders are now increasingly recognized as important considerations in the differential diagnosis of early-onset or treatment-resistant hypertension. By elucidating how molecular mechanisms govern sodium transport and hormonal regulation in distal nephrons, these disorders provide a mechanistic framework connecting tubular transport defects to systemic electrolyte imbalance and blood pressure dysregulation [2,14,15,42,43].

Importantly, recognition of these genetic disorders has direct clinical implications. Characteristic biochemical signatures, such as hypokalemia in Liddle syndrome and AME, or hyperkalemia in Gordon syndrome, can provide important diagnostic clues that guide targeted genetic testing. Mechanism-based therapies, such as ENaC inhibitors, thiazide diuretics, or MR-directed interventions, demonstrate how insights from monogenic diseases can translate directly into precision treatment strategies [6,37,43].

Future studies are increasingly focused on the broader genetic architecture of hypertension. Beyond rare monogenic disorders, emerging studies are exploring polygenic risk scores that incorporate multiple common variants affecting renal sodium transport pathways [44,45]. These low-penetrance variants may help explain inter-individual differences in salt sensitivity and susceptibility to hypertension [46,47].

As genetic testing becomes increasingly accessible, incorporating genomic data into clinical practice may reshape hypertension diagnosis. Future nephrology efforts may focus on mechanism- and genetics-based treatment strategies, in which hypertension management is tailored to the underlying molecular defect, thereby addressing the hidden renal drivers of this global disease.